Evidence map›Paper›PMID 38045341›Full record

ArticlebioRxiv : the preprint server for biology2023

A Potent Kalihinol Analogue Disrupts Apicoplast Function and Vesicular Trafficking in

Z Chahine, S Abel, T Hollin, J H Chung, G L Barnes, M E Daub, I Renard, J Y Choi, V Pratap, A Pal and 19 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 6 institutions in 2 countries.

Z ChahineDepartment of Molecular, Cell and Systems Biology, University of California Riverside, CA, USA.ORCID 0000-0001-8208-5869
S AbelDepartment of Molecular, Cell and Systems Biology, University of California Riverside, CA, USA.
T HollinDepartment of Molecular, Cell and Systems Biology, University of California Riverside, CA, USA.
J H ChungDepartment of Chemistry, University of California, Irvine, California, 92617, USA.
G L BarnesDepartment of Chemistry, University of California, Irvine, California, 92617, USA.
M E DaubDepartment of Chemistry, University of California, Irvine, California, 92617, USA.
I RenardDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
J Y ChoiDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
V PratapDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
A PalDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
M Alba-ArgomanizDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.
Cas BanksStowers Institute for Medical Research, 1000 E. 50th Street, Kansas City, MO 64110, USA.
J KirkwoodMetabolomics Core Facility, University of California, Riverside, CA 92521, USA.
A SarafStowers Institute for Medical Research, 1000 E. 50th Street, Kansas City, MO 64110, USA.
I CaminoGSK, C/ Severo Ochoa, 2 PTM, 28760 Tres Cantos (Madrid), Spain.
P CastanedaGSK, C/ Severo Ochoa, 2 PTM, 28760 Tres Cantos (Madrid), Spain.
M C CuevasGSK, C/ Severo Ochoa, 2 PTM, 28760 Tres Cantos (Madrid), Spain.
J De Mercado-ArnanzGSK, C/ Severo Ochoa, 2 PTM, 28760 Tres Cantos (Madrid), Spain.
E Fernandez-AlvaroGSK, C/ Severo Ochoa, 2 PTM, 28760 Tres Cantos (Madrid), Spain.
A Garcia-PerezGSK, C/ Severo Ochoa, 2 PTM, 28760 Tres Cantos (Madrid), Spain.
N IbarzGSK, C/ Severo Ochoa, 2 PTM, 28760 Tres Cantos (Madrid), Spain.
S Viera-MorillaGSK, C/ Severo Ochoa, 2 PTM, 28760 Tres Cantos (Madrid), Spain.
J PrudhommeDepartment of Molecular, Cell and Systems Biology, University of California Riverside, CA, USA.
C J JoynerDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.
A K BeiDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
L FlorensStowers Institute for Medical Research, 1000 E. 50th Street, Kansas City, MO 64110, USA.
C Ben MamounDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
C D VanderwalDepartment of Chemistry, University of California, Irvine, California, 92617, USA.
K G Le RochDepartment of Molecular, Cell and Systems Biology, University of California Riverside, CA, USA.
GMV Innovating Solutions (Spain) · ESUniversity of California, Riverside · USYale University · USUniversity of California, Irvine · USStowers Institute for Medical Research · USUniversity of Georgia · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Fosinopril analogs for the treatment of human babesiosisR01AI153100 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2021 to 2025
$3.6M
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria TreatmentR01AI138139 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BEN MAMOUN, CHOUKRI, LE ROCH, KARINE GAELLE · 2018 to 2022
$3.6M
Evaluating the Functional Impact of Genetic Diversity on Malaria Vaccine CandidatesR01AI168238 · NIAID · YALE UNIVERSITY · PI Amy Kristine Bei · 2022 to 2026
$3.5M
Development of endochin-like quinolones for babesiosis therapyR01AI123321 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2017 to 2020
$2.7M
Antigen Discovery and Vaccine Development for Human Babesia ParasitesR01AI152220 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2020 to 2024
$2.1M
An antigen-detection assay to diagnose Babesia microti infectionR44AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2020 to 2022
$2.1M
Employing genetic and genomic surveillance to reveal mechanisms of malaria parasite persistenceK01TW010496 · FIC · YALE UNIVERSITY · PI BEI, AMY KRISTINE · 2016 to 2021
$754k
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
An antigen-detection assay to diagnose Babesia microti infectionR43AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2018 to 2018
$300k
FIC NIH HHS K01 TW010496NIAID NIH HHS R01 AI123321NIAID NIH HHS R01 AI138139NIAID NIH HHS R01 AI152220NIAID NIH HHS R01 AI153100NIAID NIH HHS R01 AI168238NIAID NIH HHS R43 AI136118NIAID NIH HHS R44 AI136118NIH HHS P51 OD011132NIH HHS S10 OD026929
6 · The paper itself

Abstract

Here we report the discovery of MED6-189, a new analogue of the kalihinol family of isocyanoterpene (ICT) natural products. MED6-189 is effective against drug-sensitive and -resistant

Identifiers

PMID38045341
PMCPMC10690269
OpenAlexW4388893518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.